Biomarkers in Heart Failure: From Research to Clinical Practice

Area of Science:

• Cardiology
• Biomarker Discovery
• Heart Failure Management

Background:

• Heart failure (HF) diagnosis and management rely on clinical assessment and traditional biomarkers.
• There is a need for more precise and personalized approaches to HF care.
• Circulating biomarkers offer potential for improved risk stratification and treatment guidance.

Purpose of the Study:

• To review current evidence on circulating cardiac biomarkers for heart failure (HF).
• To identify a potential biomarker model for personalized, point-of-care HF management.
• To discuss future directions in biomarker research for HF.

Main Methods:

• Narrative review of contemporary evidence on HF biomarkers.
• Classification of biomarkers into functional clusters (e.g., myocardial stretch, inflammation, fibrosis).
• Analysis of benefits and drawbacks of biomarker-guided HF management.

Main Results:

• Multiple clusters of biomarkers are associated with HF pathophysiology.
• Biomarker-guided management offers potential benefits but also presents challenges.
• Genomic, transcriptomic, proteomic, and metabolomic evaluations represent future frontiers.

Conclusions:

• Circulating cardiac biomarkers are crucial for understanding HF.
• Developing robust biomarker models is key for personalized, point-of-care HF management.
• Further research is needed to enhance biomarker predictability and reproducibility.